Design, synthesis, molecular docking, and some metabolic enzyme inhibition properties of novel quinazolinone derivatives

dc.contributor.authorTokali, Feyzi S.
dc.contributor.authorTaslimi, Parham
dc.contributor.authorDemircioglu, Ibrahim H.
dc.contributor.authorKaraman, Muhammet
dc.contributor.authorGultekin, Mehmet S.
dc.contributor.authorGülçin, İlhami
dc.contributor.authorSendil, Kiyilcim
dc.contributor.authorTaslimi, Parham
dc.date.accessioned2025-10-18T13:23:12Z
dc.date.created2021
dc.date.issued2021
dc.departmentFakülteler, Fen Fakültesi, Biyoteknoloji Bölümü
dc.description.abstract3-Amino-2-ethylquinazolin-4(3H)-one (3) was synthesized in two steps from the reaction of amide (2), which was obtained from the treatment of methyl anthranilate (1) with propionyl chloride, with hydrazine. From the reaction of 3-amino-2-ethylquinazolin-4(3H)-one (3) with various aromatic aldehydes, novel benzylidenaminoquinazolin-4(3H)-one (3a-n) derivatives were synthesized. The structures of the novel molecules were characterized using infrared spectroscopy, nuclear magnetic resonance spectroscopy (H-1-NMR and C-13-NMR), and high-resolution mass spectroscopy. The novel compounds were tested against some metabolic enzymes, including alpha-glucosidase (alpha-Glu), acetylcholinesterase (AChE), and human carbonic anhydrases I and II (hCA I and II). The novel compounds showed K-i values in the range of 244-988 nM for hCA I, 194-900 nM for hCA II, 30-156 nM for AChE, and 215-625 nM for alpha-Glu. The binding affinities of the most active compounds were calculated as -7.636, -6.972, -10.080, and -8.486 kcal/mol for hCA I, hCA II, AChE, and alpha-Glu enzymes, respectively. The aromatic ring of the quinazoline moiety plays a critical role in the inhibition of the enzymes.
dc.identifier.doi10.1002/ardp.202000455
dc.identifier.issn0365-6233
dc.identifier.issn1521-4184
dc.identifier.issue5
dc.identifier.orcidTOKALI, Feyzi Sinan/0000-0001-5532-8802
dc.identifier.orcidGulcin, ilhami/0000-0001-5993-1668
dc.identifier.orcidTaslimi, Parham/0000-0002-3171-0633
dc.identifier.orcidKaraman, Muhammet/0000-0002-0155-3390
dc.identifier.pmid33537994
dc.identifier.scopus2-s2.0-85100329254
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1002/ardp.202000455
dc.identifier.urihttps://hdl.handle.net/11772/22739
dc.identifier.volume354
dc.identifier.wosWOS:000614426900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofArchiv Der Pharmazie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzWoS_20251016
dc.subject3- Aminoquinazolin- 4(3h)- One
dc.subjectEnzyme Inhibition
dc.subjectMetabolic Enzymes
dc.subjectMolecular Docking
dc.subjectSchiff Bases
dc.titleDesign, synthesis, molecular docking, and some metabolic enzyme inhibition properties of novel quinazolinone derivatives
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationdadfa319-65b8-4543-92b4-bea49e0139e9
relation.isAuthorOfPublication.latestForDiscoverydadfa319-65b8-4543-92b4-bea49e0139e9

Dosyalar